Do analysts recommend QNTM or BNR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate QNTM or GANX?

Gain Therapeutics has a consensus target price of $7.50, indicating a potential upside of 275.00%. Given Gain Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Gain Therapeutics is more favorable than Quantum Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Gain Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67

Is QNTM or GANX more profitable?

Gain Therapeutics' return on equity of -161.59% beat Quantum Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Quantum Biopharma N/A -582.23% -184.20% Gain Therapeutics N/A -161.59% -118.36%

Do analysts rate QNTM or RLYB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Rallybio 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts recommend QNTM or ACRV?

Acrivon Therapeutics has a consensus target price of $13.50, suggesting a potential upside of 513.64%. Given Acrivon Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Acrivon Therapeutics is more favorable than Quantum Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Acrivon Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has better valuation and earnings, QNTM or ACRV?

Acrivon Therapeutics is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Quantum Biopharma N/A N/A -$26.17M -$5.49 N/A Acrivon Therapeutics N/A N/A -$77.90M -$1.88 N/A

Is QNTM or ACRV more profitable?

Acrivon Therapeutics' return on equity of -70.14% beat Quantum Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Quantum Biopharma N/A -582.23% -184.20% Acrivon Therapeutics N/A -70.14% -61.60%

Do analysts rate QNTM or ATRA?

Atara Biotherapeutics has a consensus price target of $9.50, suggesting a potential upside of 0.42%. Given Atara Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Atara Biotherapeutics is more favorable than Quantum Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Atara Biotherapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Quantum Biopharma (QNTM) Competitors

$3.24 -0.20 (-5.81%)

Closing price 08/24/2026 04:00 PM Eastern

Extended Trading

$3.26 +0.02 (+0.49%)

As of 04:00 AM Eastern

Compare

QNTM vs. BNR, GANX, RLYB, ACRV, and ATRA

Should you buy Quantum Biopharma stock or one of its competitors? Quantum Biopharma's main competitors and comparable companies include Burning Rock Biotech (BNR), Gain Therapeutics (GANX), Rallybio (RLYB), Acrivon Therapeutics (ACRV), and Atara Biotherapeutics (ATRA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Quantum Biopharma compare to Burning Rock Biotech?

Quantum Biopharma (NASDAQ:QNTM) and Burning Rock Biotech (NASDAQ:BNR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Quantum Biopharma has a net margin of 0.00% compared to Burning Rock Biotech's net margin of -11.57%. Burning Rock Biotech's return on equity of -10.98% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quantum Biopharma	N/A	-582.23%	-184.20%
Burning Rock Biotech	-11.57%	-10.98%	-7.33%

In the previous week, Quantum Biopharma had 3 more articles in the media than Burning Rock Biotech. MarketBeat recorded 3 mentions for Quantum Biopharma and 0 mentions for Burning Rock Biotech. Burning Rock Biotech's average media sentiment score of 0.00 beat Quantum Biopharma's score of -0.24 indicating that Burning Rock Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Quantum Biopharma	Neutral
Burning Rock Biotech	Neutral

Burning Rock Biotech has higher revenue and earnings than Quantum Biopharma. Burning Rock Biotech is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quantum Biopharma	N/A	N/A	-$26.17M	-$5.49	N/A
Burning Rock Biotech	$77.16M	1.35	-$7.92M	-$0.82	N/A

1.2% of Quantum Biopharma shares are held by institutional investors. Comparatively, 30.0% of Burning Rock Biotech shares are held by institutional investors. 8.5% of Quantum Biopharma shares are held by company insiders. Comparatively, 30.3% of Burning Rock Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Quantum Biopharma has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market. Comparatively, Burning Rock Biotech has a beta of 1.34, meaning that its share price is 34% more volatile than the broader market.

Summary

Burning Rock Biotech beats Quantum Biopharma on 9 of the 12 factors compared between the two stocks.

How does Quantum Biopharma compare to Gain Therapeutics?

Quantum Biopharma (NASDAQ:QNTM) and Gain Therapeutics (NASDAQ:GANX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, valuation and media sentiment.

1.2% of Quantum Biopharma shares are held by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are held by institutional investors. 8.5% of Quantum Biopharma shares are held by insiders. Comparatively, 4.2% of Gain Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Gain Therapeutics has higher revenue and earnings than Quantum Biopharma. Gain Therapeutics is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quantum Biopharma	N/A	N/A	-$26.17M	-$5.49	N/A
Gain Therapeutics	$50K	1,745.60	-$20.16M	-$0.50	N/A

Quantum Biopharma has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market. Comparatively, Gain Therapeutics has a beta of 0.19, meaning that its share price is 81% less volatile than the broader market.

Gain Therapeutics' return on equity of -161.59% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quantum Biopharma	N/A	-582.23%	-184.20%
Gain Therapeutics	N/A	-161.59%	-118.36%

In the previous week, Quantum Biopharma had 3 more articles in the media than Gain Therapeutics. MarketBeat recorded 3 mentions for Quantum Biopharma and 0 mentions for Gain Therapeutics. Gain Therapeutics' average media sentiment score of 1.89 beat Quantum Biopharma's score of -0.24 indicating that Gain Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Quantum Biopharma	Neutral
Gain Therapeutics	Very Positive

Gain Therapeutics has a consensus target price of $7.50, indicating a potential upside of 275.00%. Given Gain Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Gain Therapeutics is more favorable than Quantum Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Gain Therapeutics beats Quantum Biopharma on 10 of the 14 factors compared between the two stocks.

How does Quantum Biopharma compare to Rallybio?

Quantum Biopharma (NASDAQ:QNTM) and Rallybio (NASDAQ:RLYB) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, media sentiment, risk, earnings and profitability.

Rallybio has higher revenue and earnings than Quantum Biopharma. Rallybio is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quantum Biopharma	N/A	N/A	-$26.17M	-$5.49	N/A
Rallybio	$646K	138.12	-$8.98M	-$4.34	N/A

Quantum Biopharma has a beta of 0.45, indicating that its stock price is 55% less volatile than the broader market. Comparatively, Rallybio has a beta of -0.9, indicating that its stock price is 190% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Rallybio	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

1.2% of Quantum Biopharma shares are held by institutional investors. Comparatively, 90.3% of Rallybio shares are held by institutional investors. 8.5% of Quantum Biopharma shares are held by company insiders. Comparatively, 10.3% of Rallybio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Quantum Biopharma has a net margin of 0.00% compared to Rallybio's net margin of -911.07%. Rallybio's return on equity of -40.53% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quantum Biopharma	N/A	-582.23%	-184.20%
Rallybio	-911.07%	-40.53%	-38.13%

In the previous week, Quantum Biopharma had 3 more articles in the media than Rallybio. MarketBeat recorded 3 mentions for Quantum Biopharma and 0 mentions for Rallybio. Rallybio's average media sentiment score of 0.00 beat Quantum Biopharma's score of -0.24 indicating that Rallybio is being referred to more favorably in the news media.

Company	Overall Sentiment
Quantum Biopharma	Neutral
Rallybio	Neutral

Summary

Rallybio beats Quantum Biopharma on 9 of the 13 factors compared between the two stocks.

How does Quantum Biopharma compare to Acrivon Therapeutics?

Quantum Biopharma (NASDAQ:QNTM) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Acrivon Therapeutics has a consensus target price of $13.50, suggesting a potential upside of 513.64%. Given Acrivon Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Acrivon Therapeutics is more favorable than Quantum Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Quantum Biopharma has a beta of 0.45, indicating that its share price is 55% less volatile than the broader market. Comparatively, Acrivon Therapeutics has a beta of 1.85, indicating that its share price is 85% more volatile than the broader market.

Acrivon Therapeutics is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quantum Biopharma	N/A	N/A	-$26.17M	-$5.49	N/A
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$1.88	N/A

Acrivon Therapeutics' return on equity of -70.14% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quantum Biopharma	N/A	-582.23%	-184.20%
Acrivon Therapeutics	N/A	-70.14%	-61.60%

In the previous week, Acrivon Therapeutics had 1 more articles in the media than Quantum Biopharma. MarketBeat recorded 4 mentions for Acrivon Therapeutics and 3 mentions for Quantum Biopharma. Quantum Biopharma's average media sentiment score of -0.24 beat Acrivon Therapeutics' score of -0.25 indicating that Quantum Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Quantum Biopharma	Neutral
Acrivon Therapeutics	Neutral

1.2% of Quantum Biopharma shares are owned by institutional investors. Comparatively, 71.6% of Acrivon Therapeutics shares are owned by institutional investors. 8.5% of Quantum Biopharma shares are owned by company insiders. Comparatively, 10.5% of Acrivon Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Acrivon Therapeutics beats Quantum Biopharma on 10 of the 13 factors compared between the two stocks.

How does Quantum Biopharma compare to Atara Biotherapeutics?

Quantum Biopharma (NASDAQ:QNTM) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.

Quantum Biopharma has a beta of 0.45, suggesting that its stock price is 55% less volatile than the broader market. Comparatively, Atara Biotherapeutics has a beta of 0.12, suggesting that its stock price is 88% less volatile than the broader market.

Atara Biotherapeutics has higher revenue and earnings than Quantum Biopharma. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quantum Biopharma	N/A	N/A	-$26.17M	-$5.49	N/A
Atara Biotherapeutics	$120.77M	0.79	$32.69M	-$1.18	N/A

1.2% of Quantum Biopharma shares are held by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are held by institutional investors. 8.5% of Quantum Biopharma shares are held by company insiders. Comparatively, 41.2% of Atara Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Atara Biotherapeutics has a consensus price target of $9.50, suggesting a potential upside of 0.42%. Given Atara Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Atara Biotherapeutics is more favorable than Quantum Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Quantum Biopharma has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -269.42%. Atara Biotherapeutics' return on equity of -79.12% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quantum Biopharma	N/A	-582.23%	-184.20%
Atara Biotherapeutics	-269.42%	-79.12%	-73.01%

In the previous week, Quantum Biopharma had 3 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 3 mentions for Quantum Biopharma and 0 mentions for Atara Biotherapeutics. Atara Biotherapeutics' average media sentiment score of 0.00 beat Quantum Biopharma's score of -0.24 indicating that Atara Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Quantum Biopharma	Neutral
Atara Biotherapeutics	Neutral

Summary

Atara Biotherapeutics beats Quantum Biopharma on 11 of the 15 factors compared between the two stocks.

Get Quantum Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QNTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QNTM vs. The Competition

Export

Metric	Quantum Biopharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$22.01M	$4.01B	$7.36B	$12.81B
Dividend Yield	N/A	3.64%	2.54%	10.78%
P/E Ratio	-0.59	11.69	270.56	24.05
Price / Sales	N/A	1,414.76	639.15	105.26
Price / Cash	N/A	44.94	29.03	36.89
Price / Book	2.42	17.37	11.21	6.40
Net Income	-$26.17M	-$22.72M	$3.46B	$347.95M
7 Day Performance	-2.99%	2.52%	1.74%	1.49%
1 Month Performance	8.36%	9.81%	7.34%	5.15%
1 Year Performance	-81.69%	57.46%	26.13%	17.01%

Quantum Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QNTM Quantum Biopharma	0.5938 of 5 stars	$3.24 -5.8%	N/A	-82.1%	$22.01M	N/A	N/A	N/A
BNR Burning Rock Biotech	1.0663 of 5 stars	$9.31 +2.3%	N/A	+6.1%	$92.88M	$77.16M	N/A	1,390	Gap Up
GANX Gain Therapeutics	2.786 of 5 stars	$2.03 -0.5%	$7.50 +269.5%	+1.5%	$92.52M	$50K	N/A	20
RLYB Rallybio	0.9141 of 5 stars	$16.77 -1.4%	N/A	+235.5%	$90.28M	$646K	N/A	40
ACRV Acrivon Therapeutics	3.4491 of 5 stars	$2.05 flat	$13.50 +558.5%	+61.8%	$87.74M	N/A	N/A	58

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QNTM) was last updated on 8/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Quantum Biopharma (QNTM) Competitors

QNTM vs. BNR, GANX, RLYB, ACRV, and ATRA

How does Quantum Biopharma compare to Burning Rock Biotech?

Summary

How does Quantum Biopharma compare to Gain Therapeutics?

Summary

How does Quantum Biopharma compare to Rallybio?

Summary

How does Quantum Biopharma compare to Acrivon Therapeutics?

Summary

How does Quantum Biopharma compare to Atara Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNTM vs. The Competition

Quantum Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Quantum Biopharma (QNTM) Competitors

QNTM vs. BNR, GANX, RLYB, ACRV, and ATRA

How does Quantum Biopharma compare to Burning Rock Biotech?

Do analysts recommend QNTM or BNR?

Is QNTM or BNR more profitable?

Does the media favor QNTM or BNR?

Which has better earnings & valuation, QNTM or BNR?

Do insiders and institutionals have more ownership in QNTM or BNR?

Which has more volatility and risk, QNTM or BNR?

Summary

How does Quantum Biopharma compare to Gain Therapeutics?

Do institutionals & insiders have more ownership in QNTM or GANX?

Which has higher earnings and valuation, QNTM or GANX?

Which has more risk and volatility, QNTM or GANX?

Is QNTM or GANX more profitable?

Does the media refer more to QNTM or GANX?

Do analysts rate QNTM or GANX?

Summary

How does Quantum Biopharma compare to Rallybio?

Which has preferable valuation and earnings, QNTM or RLYB?

Which has more volatility and risk, QNTM or RLYB?

Do analysts rate QNTM or RLYB?

Do institutionals and insiders have more ownership in QNTM or RLYB?

Is QNTM or RLYB more profitable?

Does the media refer more to QNTM or RLYB?

Summary

How does Quantum Biopharma compare to Acrivon Therapeutics?

Do analysts recommend QNTM or ACRV?

Which has more volatility & risk, QNTM or ACRV?

Which has better valuation and earnings, QNTM or ACRV?

Is QNTM or ACRV more profitable?

Does the media prefer QNTM or ACRV?

Do institutionals & insiders hold more shares of QNTM or ACRV?

Summary

How does Quantum Biopharma compare to Atara Biotherapeutics?

Which has more risk and volatility, QNTM or ATRA?

Which has higher valuation and earnings, QNTM or ATRA?

Do insiders and institutionals hold more shares of QNTM or ATRA?

Do analysts rate QNTM or ATRA?

Is QNTM or ATRA more profitable?

Does the media prefer QNTM or ATRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNTM vs. The Competition

Quantum Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools